Biogen's Early-Stage Alzheimer's Data Continues to Impress Post author:Sam Post published:November 1, 2017 Post category:BioPharma ALZ’s researchers continue to see hope in Biogen’s aducanumab. Source: BioSpace You Might Also Like FDA Raises Big Safety Concerns With Johnson & Johnson's Arthritis Drug Sirukumab July 30, 2017 Feds Appeared at Perrigo's HQ With Search Warrants Yesterday May 2, 2017 AmerisourceBergen Pays $815M Cash for Drug Wholesaler H. D. Smith November 20, 2017
